Matthew Biegler
Stock Analyst at Oppenheimer
(3.71)
# 1,999
Out of 4,357 analysts
418
Total ratings
40.4%
Success rate
4.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Reiterated: Buy | $7 | $2.15 | +225.58% | 9 | May 14, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $50 | $30.39 | +64.53% | 23 | May 14, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $165 | $131.10 | +25.86% | 15 | May 13, 2026 | |
| CTMX CytomX Therapeutics | Reiterated: Buy | $12 | $3.45 | +247.83% | 11 | May 13, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Reiterated: Buy | $9 | $3.98 | +126.13% | 23 | May 13, 2026 | |
| NRIX Nurix Therapeutics | Reiterated: Buy | $28 | $17.39 | +61.01% | 23 | May 13, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $48 | $12.71 | +277.66% | 22 | May 13, 2026 | |
| BMEA Biomea Fusion | Reiterated: Buy | $9 | $1.39 | +547.48% | 14 | May 13, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Reiterated: Buy | $22 | $8.55 | +157.46% | 5 | May 13, 2026 | |
| RNAC Cartesian Therapeutics | Rated: Hold | n/a | $6.92 | - | 11 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $14.26 | +26.23% | 17 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $4.20 | +614.29% | 8 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $8.98 | +67.04% | 22 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $865 | $600.66 | +44.01% | 13 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $6.42 | +133.64% | 23 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $19.08 | +135.85% | 2 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $8.58 | - | 16 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.56 | +412.82% | 13 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 | $28.94 | +24.40% | 19 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.74 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $12.12 | n/a | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $14.57 | n/a | 13 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20.77 | $2.23 | n/a | 25 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11.08 → $4.15 | $0.43 | n/a | 12 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.66 | n/a | 15 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $0.3663 | n/a | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.07 | n/a | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $3.14 | n/a | 6 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $50 | $1.53 | n/a | 15 | Feb 17, 2022 |
Allogene Therapeutics
May 14, 2026
Reiterated: Buy
Price Target: $7
Current: $2.15
Upside: +225.58%
Tyra Biosciences
May 14, 2026
Reiterated: Buy
Price Target: $50
Current: $30.39
Upside: +64.53%
Gilead Sciences
May 13, 2026
Reiterated: Buy
Price Target: $165
Current: $131.10
Upside: +25.86%
CytomX Therapeutics
May 13, 2026
Reiterated: Buy
Price Target: $12
Current: $3.45
Upside: +247.83%
Zentalis Pharmaceuticals
May 13, 2026
Reiterated: Buy
Price Target: $9
Current: $3.98
Upside: +126.13%
Nurix Therapeutics
May 13, 2026
Reiterated: Buy
Price Target: $28
Current: $17.39
Upside: +61.01%
Olema Pharmaceuticals
May 13, 2026
Reiterated: Buy
Price Target: $48
Current: $12.71
Upside: +277.66%
Biomea Fusion
May 13, 2026
Reiterated: Buy
Price Target: $9
Current: $1.39
Upside: +547.48%
BridgeBio Oncology Therapeutics
May 13, 2026
Reiterated: Buy
Price Target: $22
Current: $8.55
Upside: +157.46%
Cartesian Therapeutics
May 12, 2026
Rated: Hold
Price Target: n/a
Current: $6.92
Upside: -
May 6, 2026
Reiterated: Buy
Price Target: $18
Current: $14.26
Upside: +26.23%
May 6, 2026
Reiterated: Buy
Price Target: $30
Current: $4.20
Upside: +614.29%
May 5, 2026
Reiterated: Buy
Price Target: $15
Current: $8.98
Upside: +67.04%
Apr 30, 2026
Reiterated: Buy
Price Target: $865
Current: $600.66
Upside: +44.01%
Apr 28, 2026
Reiterated: Buy
Price Target: $15
Current: $6.42
Upside: +133.64%
Mar 27, 2026
Reiterated: Buy
Price Target: $45
Current: $19.08
Upside: +135.85%
Feb 26, 2026
Reiterated: Hold
Price Target: n/a
Current: $8.58
Upside: -
Nov 14, 2025
Reiterated: Buy
Price Target: $8
Current: $1.56
Upside: +412.82%
Nov 4, 2025
Reiterated: Buy
Price Target: $36
Current: $28.94
Upside: +24.40%
May 14, 2025
Reiterated: Hold
Price Target: n/a
Current: $2.74
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: n/a
Current: $12.12
Upside: n/a
Dec 9, 2024
Maintained: Buy
Price Target: $160
Current: $14.57
Upside: n/a
Oct 31, 2023
Maintained: Buy
Price Target: $20.77
Current: $2.23
Upside: n/a
Aug 14, 2023
Maintained: Buy
Price Target: $11.08 → $4.15
Current: $0.43
Upside: n/a
Jul 31, 2023
Rated: Hold
Price Target: n/a
Current: $11.66
Upside: n/a
Mar 2, 2023
Maintained: Buy
Price Target: $18
Current: $0.3663
Upside: n/a
Dec 22, 2022
Downgraded: Hold
Price Target: n/a
Current: $1.07
Upside: n/a
Dec 22, 2022
Downgraded: Hold
Price Target: n/a
Current: $3.14
Upside: n/a
Feb 17, 2022
Maintained: Buy
Price Target: $8 → $50
Current: $1.53
Upside: n/a